Ran Nussbaum - 21 Oct 2022 Form 4/A - Amendment Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
21 Oct 2022
Net transactions value
+$285,114
Form type
4/A - Amendment
Filing time
28 Feb 2023, 11:23:21 UTC
Date Of Original Report
25 Oct 2022
Previous filing
28 Feb 2023
Next filing
30 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise $285,114 +47,999 +3.3% $5.94 1,485,168 21 Oct 2022 Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Options Exercise $0 -32,723 -100% $0.000000* 0 21 Oct 2022 Ordinary Shares 32,723 $5.94 By Pontifax (Israel) III Limited Partnership
transaction URGN Stock Option (right to buy) Options Exercise $0 -15,276 -100% $0.000000* 0 21 Oct 2022 Ordinary Shares 15,276 $5.94 By Pontifax Cayman III Limited Partnership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,481,927 shares of securities beneficially owned following reported transaction instead of 1,485,168 shares.